CJC-1295

Research

CJC-1295 (with/without DAC)

Category
Growth Hormone
Aliases
DAC:GRF, Modified GRF 1-29
Administration
Subcutaneous injection

Overview

Long-acting GHRH analog engineered for extended half-life. Stimulates pulsatile growth hormone secretion and downstream IGF-1 production.

Treatments studied

Treatment categories

Age-related decline

Counteracts the natural decline in growth hormone secretion associated with aging.

Body composition

Elevated IGF-1 supports fat loss and lean muscle maintenance over time.

Growth hormone deficiency

Provides sustained GHRH receptor stimulation, prompting the pituitary to release more growth hormone.

Longevity

Researched for its potential to support the growth hormone axis, which is linked to several markers of healthy aging.